By Olivia Bugault

 

Merck KGaA said Tuesday that it has invested 100 million euros ($108.9 million) for the construction of a new facility in California that will increase its gene therapy capacity.

The German pharmaceuticals and chemicals company said the facility, which should open next year, will be used for its BioReliance(R) viral and gene therapy service offering.

Merck KGaA already has a facility in California manufacturing gene therapies.

"Merck's new, 140,000-square-foot manufacturing facility will support viral and gene therapy production at the 1000-liter scale using its Mobius(R) single-use equipment," it said.

 

Write to Olivia Bugault at olivia.bugault@wsj.com

 

(END) Dow Jones Newswires

April 21, 2020 08:52 ET (12:52 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Merck KGaA (PK) Charts.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Merck KGaA (PK) Charts.